Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Volpe

Showing results (21-30 of 820) with videos related to

Pageof 82
Sort By:
European Heart Journal|January 11, 2021
Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problemsCarlo Patrono, Massimo Volpe
European Heart Journal|June 3, 2021
Unhealthy lifestyles mediate only a small proportion of the socioeconomic inequalities' impact on cardiovascular outcomes in US and UK adults: a call for action for social cardiologyGiovanna Liuzzo, Massimo Volpe
European Heart Journal|July 10, 2024
Weekly Journal Scan: a 'thousand-mile' journey in obesity-related heart failure treatment begins with a few STEPsDaniela Pedicino, Massimo Volpe
European Heart Journal|March 28, 2024
Weekly journal scan: a hard RAFTing to improve long-term survival in heart failure with severely reduced ejection fractionDaniela Pedicino, Massimo Volpe
European Heart Journal|April 15, 2024
Weekly journal scan: excess incidence of unexpected health outcomes following myocardial infarction-broader paths for secondary preventionLeonarda Galiuto, Massimo Volpe
Vascular Pharmacology|September 22, 2023
Hypertension, coronary artery disease and myocardial ischemic syndromesMassimo Volpe, Giovanna Gallo
High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension|August 30, 2020
COVID-19 and the Forgotten MajorityMassimo Volpe, Giovanna Gallo
European Heart Journal|December 9, 2020
Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors?Massimo Volpe, Carlo Patrono
European Heart Journal|January 3, 2022
Blood pressure lowering drugs differ in their capacity to prevent type 2 diabetesMassimo Volpe, Carlo Patrono
European Heart Journal|December 14, 2021
FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney diseaseGiovanna Liuzzo, Massimo Volpe
Pageof 82

Showing results (21-30 of 820) with videos related to

Sort By:
Pageof 82
European Heart Journal|January 11, 2021
Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problemsCarlo Patrono, Massimo Volpe
European Heart Journal|June 3, 2021
Unhealthy lifestyles mediate only a small proportion of the socioeconomic inequalities' impact on cardiovascular outcomes in US and UK adults: a call for action for social cardiologyGiovanna Liuzzo, Massimo Volpe
European Heart Journal|July 10, 2024
Weekly Journal Scan: a 'thousand-mile' journey in obesity-related heart failure treatment begins with a few STEPsDaniela Pedicino, Massimo Volpe
European Heart Journal|March 28, 2024
Weekly journal scan: a hard RAFTing to improve long-term survival in heart failure with severely reduced ejection fractionDaniela Pedicino, Massimo Volpe
European Heart Journal|April 15, 2024
Weekly journal scan: excess incidence of unexpected health outcomes following myocardial infarction-broader paths for secondary preventionLeonarda Galiuto, Massimo Volpe
Vascular Pharmacology|September 22, 2023
Hypertension, coronary artery disease and myocardial ischemic syndromesMassimo Volpe, Giovanna Gallo
High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension|August 30, 2020
COVID-19 and the Forgotten MajorityMassimo Volpe, Giovanna Gallo
European Heart Journal|December 9, 2020
Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors?Massimo Volpe, Carlo Patrono
European Heart Journal|January 3, 2022
Blood pressure lowering drugs differ in their capacity to prevent type 2 diabetesMassimo Volpe, Carlo Patrono
European Heart Journal|December 14, 2021
FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney diseaseGiovanna Liuzzo, Massimo Volpe
Pageof 82